SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PTN - Palatin Technologies Inc.
PTN 14.71-8.1%Dec 26 3:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: rareearth4212/2/2006 11:09:12 PM
   of 142
 
Publicity on ABC network.

abcnews.go.com

I haven't changed my mind about PTN, I'm going to continue holding through the phase 3 results, at least.

I didn't point it out on my last post, but the other interesting item I learned from the PTN phase 2b results is the probable explanation for MRK discontinuing their weight loss program. The BS explanation from someone on the Yahoo board, I think "lordnickraptis", was priapism. This never made sense as a reason for complete discontinuation, and I have said so repeatedly, since they would then have developed the drug just for women, because they're the larger market, anyway.

However HTN is an excellent reason not to develop a chronic drug therapy for weight loss, since obese people tend to have problems with HTN anyway, and Vioxx has associated HTN, which may contribute to the increased cardiovascular risk attributed to that drug.

However for a short-acting drug to be used once or twice weekly or thereabouts for ED, a little associated HTN in a small percentage of patients would probably be acceptable.

RE42
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext